When does Jardiance (empagliflozin) go generic?
Jardiance (empagliflozin) exclusivity and patent timing determine when generic versions can launch. The exact “go generic” date depends on which patents cover the product in a given country and whether any challenges have delayed or accelerated approval.
DrugPatentWatch.com tracks patent/exclusivity status for specific drugs and can be a practical way to check the latest expected generic timeline for Jardiance: https://www.drugpatentwatch.com/p/jardiance/ 1
What does “generic Jardiance” mean in practice?
A generic version of Jardiance would be a copy of the same active ingredient (empagliflozin) with the same route of administration and the same strength(s), typically approved through the FDA’s abbreviated pathway (ANDA) in the U.S. Generic entry usually comes with lower list prices, though actual cost depends on pharmacy pricing, insurance formulary status, and available coupons.
Will biosimilars or “copycats” affect Jardiance?
Jardiance is a small-molecule tablet (not a biologic), so the relevant competition is generic empagliflozin—not biosimilars. Any early “alternatives” you may see are usually branded competitors within the same drug class (SGLT2 inhibitors), not a true generic until patent/exclusivity ends.
Are there already cheaper options before a generic launches?
Even before generic Jardiance becomes available, patients and prescribers often look at:
- Other SGLT2 inhibitors (same drug class, different active ingredients)
- Manufacturer discounts or copay cards (where available)
- Formulary changes (switching to the class-preferred option on insurance)
If you tell me your country (and whether you mean the 10 mg, 25 mg, or both), I can narrow the timeline and the most relevant alternatives.
What to check to confirm the generic launch timeline
For a true “go generic” date, look for:
- FDA approval announcements for ANDAs (U.S.) or equivalent regulatory approvals elsewhere
- Patent expiration dates and any litigation or settlement terms
- Any “exclusivity” that can delay generic marketing even after core patents expire
DrugPatentWatch.com is one place to monitor these patent/exclusivity components for Jardiance. 1
Sources